Why Did Sun Pharma and Cipla Recall Medicines in the US?
Synopsis
Sun Pharma and Cipla's recent recalls in the US highlight critical manufacturing issues. The USFDA has classified these recalls as Class II and III, emphasizing the importance of product quality in the global pharmaceutical market. Stay informed on how these recalls may impact consumers and the industry.
Key Takeaways
Sun Pharma recalls over 26,000 bottles of a topical solution.
Cipla withdraws 15,221 syringes from the market.
Both companies face manufacturing-related issues .
Class II and Class III recalls signify different risk levels.
The importance of regulatory compliance is emphasized in the US market.
New Delhi, Jan 26 (NationPress) Indian pharmaceutical companies Sun Pharmaceutical Industries and Cipla have taken steps to recall specific products from the US market due to concerns related to manufacturing processes, as reported by the US Food and Drug Administration (USFDA).
According to the latest Enforcement Report, the US division of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication intended for treating dandruff and skin conditions that lead to inflammation and itching.
Sun Pharmaceutical Industries Inc, located in Princeton, New Jersey, has initiated a recall of 24,624 bottles of Fluocinolone Acetonide Topical Solution after it was found that the product did not meet impurity and degradation criteria.
This nationwide Class III recall in the US was announced on December 30, 2025. The USFDA clarified that a Class III recall is applicable in situations where the product’s usage is unlikely to result in adverse health effects.
The agency also indicated that Sun Pharma is recalling certain batches of Clindamycin Phosphate USP, a treatment for acne vulgaris.
This particular recall was initiated on November 26, 2025, after testing revealed impurity levels and assay values exceeding acceptable limits. This has also been categorized as a Class III recall.
In a separate announcement, the USFDA noted that Cipla's US division has recalled more than 15,000 syringes from the American market.
Cipla USA Inc, with its headquarters in Warren, New Jersey, is recalling 15,221 pre-filled syringes of Lanreotide Injection due to the detection of particulate matter.
The Class II recall was initiated by Cipla on January 2 of this year. According to the USFDA, a Class II recall is warranted when the product might result in temporary or medically reversible health effects, although the likelihood of serious harm remains low.
The United States is the largest pharmaceutical market globally, highlighting the significance of compliance with regulations and maintaining product quality for drug manufacturers operating within the country.
Point of View
It is essential to recognize the implications of these recalls on public health and the pharmaceutical industry. The rigorous standards set by the USFDA are crucial in ensuring the safety of medications. We must remain vigilant and support stringent quality checks to maintain public trust in the healthcare system.
NationPress
12 May 2026
Frequently Asked Questions
What products are being recalled by Sun Pharma?
Sun Pharma is recalling over 26,000 bottles of Fluocinolone Acetonide Topical Solution and certain batches of Clindamycin Phosphate USP due to manufacturing issues.
Why did Cipla recall its syringes?
Cipla recalled 15,221 pre-filled syringes of Lanreotide Injection due to the presence of particulate matter.
What are the recall classifications?
The recalls have been classified as Class II and Class III by the USFDA, indicating varying levels of potential health risks.
